🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. 5μg/ml ESAT6-CFP10

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial
  2. 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial
  3. 68Ga-NODAGA-SNA006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 2 small molecule active

    1 trial
  4. ADSC01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Connective Tissue Diseases

    phase 2 mab active

    1 trial
  5. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  6. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  7. ASC30 tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule active

    1 trial
  8. ASCT+CD7-CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CD7 Positive

    phase 2 small molecule active

    1 trial
  9. AUY922

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastrointestinal Stromal Tumor

    phase 2 small molecule active

    1 trial
  10. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial
  11. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial
  12. Acetohydroxamic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multidrug-Resistant Tuberculosis

    phase 2 small molecule active

    1 trial
  13. Ad-HGF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Heart Disease

    phase 2 small molecule active

    1 trial
  14. Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial
  15. Adebrelimab (PD-L1 inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer Metastatic

    phase 2 small molecule active

    1 trial
  16. Ademetionine 1,4-Butanedisulfonate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obstructive Hypertrophic Cardiomyopathy (oHCM)

    phase 2 small molecule active

    1 trial
  17. Albumin Paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  18. Alectinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bone Cancer

    phase 2 small molecule active

    1 trial
  19. Allogeneic MSC (AlloMSC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Systemic Lupus Erythematosus

    phase 2 mab active

    1 trial
  20. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  21. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Non-small Cell Stage IV

    phase 2 small molecule active

    1 trial
  22. Anlotinib combined Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  23. Anrotinib plus Tirelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial
  24. Anti-BCMA-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources